Omega 3 Fatty Acids Supplementation and Oxidative Stress in HIV-Seropositive Patients. A Clinical Trial

Abstract

HIV-seropositive patients show high incidence of coronary heart disease and oxidative stress has been described as relevant key in atherosclerosis development. The aim of this study was to assess the effect of omega 3 fatty acids on different markers of oxidative stress in HIV-seropositive patients. We performed a randomized parallel controlled clinical trial in The Instituto Mexicano del Seguro Social, a public health hospital. 70 HIV-seropositive patients aged 20 to 55 on clinical score A1, A2, B1 or B2 receiving highly active antiretroviral therapy (HAART) were studied. They were randomly assigned to receive omega 3 fatty acids 2.4 g (Zonelabs, Marblehead MA) or placebo for 6 months. At baseline and at the end of the study, anthropometric measurements, lipid profile, glucose and stress oxidative levels [nitric oxide catabolites, lipoperoxides (malondialdehyde plus 4-hydroxialkenals), and glutathione] were evaluated. Principal HAART therapy was EFV/TDF/FTC (55%) and AZT/3TC/EFV (15%) without difference between groups. Treatment with omega 3 fatty acids as compared with placebo decreased triglycerides (-0.32 vs. 0.54 mmol/L; p = 0.04), but oxidative stress markers were not different between groups.Trial RegistrationClinicalTrials.gov NCT02041520

Effect of Omega-3 Polyunsaturated Fatty Acids Treatment on Lipid Pattern of HIV Patients: A Meta-Analysis of Randomized Clinical Trials

“…An additional three studies were excluded because they reported incomplete data. Finally, nine studies were eligible and included in the meta-analysis [12][13][14][15][16][17][18][19][20]. The study selection process is shown in Figure 1.…”

“…Follow-up periods ranged between 8 weeks and 6 months and different treatment regimens were tested. All selected trials were designed with parallel groups [12][13][14][15][16][17][18][19] or were crossover [20], and all were multicenter [13,15,17] or Data were pooled from nine clinical trials comprising 18 treatment arms, which included 578 subjects, with 308 in the active-treated arm and 270 in the control one.…”

“…Follow-up periods ranged between 8 weeks and 6 months and different treatment regimens were tested. All selected trials were designed with parallel groups [12][13][14][15][16][17][18][19] or were crossover [20], and all were multicenter [13,15,17] or single-center [12,14,16,[18][19][20] clinical studies. The enrolled subjects were adult patients living with chronic HIV infection and iatrogenic dyslipidemia.…”

The West African&nbsp;<em>Sorghum Bicolor </em>Leaf Sheath Extract Jobelyn&reg; and Its Diverse Therapeutic Potentials

“…Deficiency usually results in anemia, impaired brain function, and symptoms of mental disorder. 47 The only good food sources of B 12 are primarily animal foods like meat, fish and eggs producing 2.8µg/100; 1.95µg/100; 4.15µg/100 of B12, respectively. Interestingly, SBLS is a good source of B 12 producing 0.83µg/100 g. This is the first time a plant product has been reported to contain significant amounts (34%) of vitamin B 12 .…”

In vitro Assessment of the Antioxidant Effect of Cunila microcephala Benth Infusion (Poejo) on Erythrocytes from Individuals with HIV/AIDS

“…factor (NF-kB), which is a transcription factor accelerating the viral replication process (Stephenson et al, 2006;Van Gaalen & Wahl, 2009;Amador-Licona et al, 2016).…”